Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant alone and with Montelukast in Allergic Rhinitis
NCT01804400Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fevipiprant in allergic rhinitis (AR), sponsored by Novartis. Started Oct 2012; status: completed.
02
Drugs
fevipiprant
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01804400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01804400.